EVEROLIMUS vs LAZCLUZE

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 20, 2026·How we rate

Possible drug interaction. EVEROLIMUS and LAZCLUZE are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	EVEROLIMUS	LAZCLUZE
Rating	70/100	New
Pharmacy pays	~$229.16 /30	—
Type	RX	RX
Active ingredient	EVEROLIMUS	LAZERTINIB MESYLATE
Manufacturer	Biocon Pharma	Janssen Biotech
Dosage forms	Tablet	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	Boxed warning	None
Half-life	about 30 hours (mean terminal elimination half-life)	—
Treats	—	Lung Neoplasms

everolimus lazcluze

Rating

70/100

New

Pharmacy pays

~$229.16 /30

—

Type

Active ingredient

EVEROLIMUS

LAZERTINIB MESYLATE

Manufacturer

Biocon Pharma

Janssen Biotech

Dosage forms

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Half-life

about 30 hours (mean terminal elimination half-life)

—

Treats

—

Lung Neoplasms

Frequently asked questions

What is the difference between Everolimus and Lazcluze?

Everolimus contains Everolimus, while Lazcluze contains Lazertinib Mesylate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.